Pier Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Pier Capital’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-309,299	Closed	-$4.13M	–	145
2017 Q1	$4.13M	Buy	+309,299	New	+$4.84M	0.71%	91

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Pier Capital's MNTA Position: Q2 2017 in Review

Pier Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2017, closing a stake of 309,299 shares — an estimated $4.13M sold.

Pier Capital first reported a position in MNTA in Q1 2017 and held it in 1 quarter. The position peaked at $4.13M in Q1 2017. 164 funds tracked by Wall St. Rank hold MNTA as of Q2 2017.

Pier Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Pier Capital sold 309,299 Momenta Pharmaceuticals, Inc. shares in Q2 2017, an estimated $4.13M.
Pier Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
Pier Capital's Momenta Pharmaceuticals, Inc. position peaked at $4.13M in Q1 2017.
164 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2017.

Based on Pier Capital's 13F filing for Q2 2017, filed 9 Aug 2017.